EHA 2024 | The current landscape of maintenace therapy in AML and areas for future exploration
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the current landscape of maintenance therapy in acute myeloid leukemia (AML) and outlines some areas for future exploration. Currently, only two maintenance therapies are approved, midostaurin and azacitidine, and these are only administered to a small proportion of patients – those in complete remission (CR) and ineligible for stem cell transplantation. Further research is needed into the use of these agents in younger cohorts and in patients treated with novel intensive chemotherapy regimens, such as CPX-351. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, BMS, Jazz, Servier, Novartis, Syros.
